Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 14683659.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Patients who have not received previous antiretroviral treatment (ART) have a high failure rate on the combination treatment of abacavir, lamivudine, and tenovir. We assessed the virological failure rate in eight patients with HIV-1 who switched to this combination after having complete virological suppression from their previous long-term ART (median 8.0 months, range 7.5-18.0). Five of the eight patients showed virological failure. Four of these five patients had either the K65R mutation, the M184V/I mutation, or both. This combination of drugs cannot therefore be recommended as alternative treatment in patients with HIV-1 who are fully virologically suppressed.
Medical subject headings
- Adenine
- HIV Infections
- HIV-1
- Organophosphonates
- Reverse Transcriptase Inhibitors